Runtogen
Menu
Runtogen’s specialized VHH discovery platform enables rapid isolation and optimization of single-domain antibodies from camelid immunizations or synthetic libraries. Leverage the unique benefits of nanobodies for your therapeutic, diagnostic, or research applications.
VHH antibodies, also known as nanobodies, are the recombinant variable domains of heavy-chain-only antibodies derived from camelids (llamas, alpacas, camels). They are the smallest functional antigen-binding fragments (~15 kDa), offering unique advantages over conventional antibodies.
Exceptional stability, solubility, and tissue penetration. Their small size allows access to cryptic epitopes (e.g., enzyme active sites, GPCR pockets) not easily targeted by conventional mAbs. Ideal for bispecifics, CAR-T, and intracellular delivery.
From animal immunization to validated lead candidates, our end-to-end platform ensures high success rates for even the most challenging targets.
Custom immunization of llamas or alpacas with your target (protein, peptide, cells). We construct high-diversity immune or naïve VHH libraries.
Robust biopanning against soluble antigens, membrane proteins, or whole cells to enrich target-specific VHH binders.
ELISA, FACS, or SPR-based screening to identify clones with optimal affinity, specificity, and biophysical properties.
Affinity maturation, humanization, Fc-fusion, or multi-specific formatting. Functional validation in relevant assays.
Small size and extended CDR3 loops allow VHHs to bind enzyme active sites, GPCR cavities, and viral grooves inaccessible to conventional antibodies.
Robust folding and stability at high temperatures or in the presence of detergents/chaotropic agents. Ideal for industrial and therapeutic use.
Easily formatted as mono-, bi-, or multi-specific constructs, fused to Fc, toxins, or drugs. Simplify complex biologics engineering.
Humanization available to reduce potential immunogenicity while retaining affinity and stability.
Expedited discovery programs: lead candidates in as little as 10–12 weeks from immunization.
Specialized platforms for isolating VHHs against multi-pass membrane proteins (GPCRs, ion channels) in native-like conformations.
From oncology and inflammation to infectious diseases. VHHs are building blocks for CAR-T, bispecific T-cell engagers, and half-life extended biologics.
Exceptional stability enables robust point-of-care tests, lateral flow assays, and in vivo imaging agents.
Intracellular staining (chromobodies), conformational sensors, and crystallization chaperones for structural biology.
Contact our team of nanobody experts to discuss your target and receive a tailored proposal within 24 hours.
Request a consultation →📧 [email protected] | 📞 +1 (303) 522-8502